Additionally, our comprehensive pan-cancer analysis suggested that METTL3 is involved in regulating the tumor immune microenvironments and epithelial–mesenchymal transition via modulating RNA modification and metabolism, making it a potential therapeutic target. This evidence concerns the gene METTL3 and cancer.